Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions

Human Gene Therapy

Volumn 13, Issue 1, 2002, Pages 15-63

  Harvey, Ben Gary ^a   Maroni, Jaman ^a   O’donoghue, Kelley A ^a   Chu, Karen W ^b   Muscat, Jolene C ^a   Pippo, Allison L ^a   Wright, Connie E ^a   Hollmann, Charleen ^a   Wisnivesky, Juan P ^a   Kessler, Paul D ^b   Rasmussen, Henrik S ^b   Rosengart, Todd K ^c   Crystal, Ronald G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b GENVEC INC   (United States)

^c EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; FLUOROURACIL; RECOMBINANT DNA; TRANSMEMBRANE CONDUCTANCE REGULATOR; VASCULOTROPIN; VIRUS VECTOR;

ADENOVIRUS; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COLON CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CYSTIC FIBROSIS; DEATH; DOSE RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; GENE TRANSFER; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; RISK ASSESSMENT; SIDE EFFECT; TRANSGENE; VIRUS SHEDDING;

ADENOVIRUSES, HUMAN; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; COMORBIDITY; CORONARY ARTERIOSCLEROSIS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYTOSINE DEAMINASE; DRUG ADMINISTRATION ROUTES; ENDOTHELIAL GROWTH FACTORS; ESCHERICHIA COLI; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; LYMPHOKINES; MALE; MIDDLE AGED; NUCLEOSIDE DEAMINASES; PERIPHERAL VASCULAR DISEASES; SAFETY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ADENOVIRIDAE;

EID: 0036149132     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340152712638     Document Type: Article

References (86)

1. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina
2. Phase I trial of gene therapy in primary brain tumor
3. A cancer gene therapy approach utilizing an anti-erbB-2 sFv encoding adenovirus: A phase I trial
4. Human gene therapy
5. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: A phase I clinical trial
6. Unexpected, late cardiovascular effects of surgery for peripheral artery disease. Veterans affairs cooperative study
7. Intermittent claudication in 8343 men and 21-year specific mortality follow-up
8. Transmyocardial laser revascularisation compared with continued medical therapy for treatment of refractory angina pectoris: A prospective randomised trial
9. Factors correlating with risk of mortality after transmyocardial revascularization
10. Grading of angina pectoris
11. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
12. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma
13. Mortality over a period of 10 years in patients with peripheral arterial disease
14. Current treatment for colorectal cancer metastatic to the liver
15. Transfer of genes to humans: Early lessons and obstacles to success
16. Administration of an adeno-virus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis
17. A phase 1 study, in cystic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis transmembrane conductance regulator gene in the lung
18. Evaluation of repeat administration of a replication deficient, recombinant adenovirus containing the normal cystic fibrosis transmembrane conductance regulator cDNA to the airways of individuals with cystic fibrosis
19. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine
20. Analysis of risk factors for local delivery of low-and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions
21. Vascular morbidity and mortality during long-term follow-up in claudicants selected for peripheral bypass surgery
22. The fate of the claudicant - A prospective study of 1969 claudicants
23. Long-term survival in patients with coronary artery disease: Importance of peripheral vascular disease
24. Pedal bypass for limb-threatening ischaemia: An 11-year review
25. Perioperative- and long-term mortality rates after major vascular surgery: The relationship to preoperative testing in the medicare population
26. Surgical therapy of hepatic colorectal metastasis
27. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease
28. Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products
29. Immune response to recombinant capsid proteins of adenovirus in humans: Antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity
30. Cellular immune responses of healthy individuals to intradermal administration of an E1-E3-adenovirus gene transfer vector
31. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs
32. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus
33. Transmyocardial laser revascularization in the patient with unmanageable unstable angina
34. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial
35. The natural history of peripheral vascular disease. Implications for its management
36. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIM.S., the Swedish ticlopidine multicentre study
37. Fate in intermittent claudication: Outcome and risk factors
38. Holmium: YAG laser transmyocardial revascularization relieves angina and improves functional status
39. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis
40. Relevance of neoadjuvant and adjuvant treatment for patients with resectable liver metastases of colorectal carcinoma
41. The influence of arterial reconstructive surgery on the outcome of critical leg ischaemia
42. Surgical treatment of chronic critical leg ischemia. A five-year follow-up of survival, mobility, and treatment level
43. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype
44. Sero-switch" adenovirus-mediated in vivo gene transfer: Circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype
45. The ankle-brachial index as a predictor of survival in patients with peripheral vascular disease
46. IL-6 release and airway administration of human CFTR cDNA adenovirus vector
47. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy
48. Results of transmyocardial laser revascularization in non-revascularizable coronary artery disease after 3 years follow-up
49. Surveillance, epidemiology, and end results
50. Heart rate adjustment of ST segment depression and performance of the exercise electrocardiogram: A critical evaluation
51. A prospective cooperative study of complications
52. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens
53. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium
54. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct in-tramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA
55. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease
56. Hypothesis testing: One-sample inference
57. Gene therapy for non-small cell lung cancer: A preliminary report of a phase I trial of adenoviral p53 gene replacement
58. Introduction to categorical statistics
59. Transmyocardial laser revascularisation in patients with refractory angina: A randomised controlled trial
60. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal tumor study group protocol 6584
61. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma
62. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and mela noma: Results of a phase 1 clinical trial
63. Safety of fiberoptic bronchoalveolar lavage in evaluation of interstitial lung disease
64. Reappraisal of coronary endarterectomy for the treatment of diffuse coronary artery disease
65. Lack of serious hepatotoxicity with adenoviral-mediated intratumoral gene therapy: A phase I trial of recombinant adenoviral vector ex pressing the herpes simplex virus thymidine kinase gene (Adv.RSV tk) and followed by intravenous ganciclovir in patients with metastatic colorectal cancer to the liver
66. Long-term prognostic value of clinically evident noncoronary vascular disease in patients undergoing coronary revascularization in the Bypass An gioplasty Revascularization Investigation (BARI)
67. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
68. Major hepatic resection. A 25-year experience
69. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors
70. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients
71. Gene therapy - Promises, problems and prospects
72. 2laser revascularization: A chance for the 'inoperable' patient
73. Surgical revascularization versus thrombolysis for nonembolic lower extremity native artery occlusions: Results of a prospective randomized trial
74. Adenovirus as gene-delivery vehicles
75. Critical and subcritical ischemia
76. Surgical treatment and other regional treatments for colorectal cancer liver metastases
77. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis
78. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis
79. Outcome and influence of age after infrainguinal revascularisation in critical limb ischemia
80. A phase I study of adenovirus-mediated transfer of the human cystic fibrosis trans-membrane conductance regulator gene to a lung segment of individuals with cystic fibrosis